3D Systems - Die nächste Apple? (Seite 69) | Diskussion im Forum
eröffnet am 05.11.12 20:43:11 von
neuester Beitrag 21.10.23 18:29:55 von
neuester Beitrag 21.10.23 18:29:55 von
Beiträge: 1.446
ID: 1.177.635
ID: 1.177.635
Aufrufe heute: 1
Gesamt: 237.192
Gesamt: 237.192
Aktive User: 0
ISIN: US88554D2053 · WKN: 888346 · Symbol: DDD
4,4900
USD
+0,90 %
+0,0400 USD
Letzter Kurs 16:37:46 NYSE
Neuigkeiten
22.03.24 · globenewswire |
09.08.23 · globenewswire |
07.08.23 · globenewswire |
31.07.23 · globenewswire |
Werte aus der Branche Hardware
Wertpapier | Kurs | Perf. % |
---|---|---|
2,3630 | +12,95 | |
1,9600 | +11,68 | |
10,530 | +11,19 | |
0,6090 | +10,73 | |
24,065 | +9,04 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,8550 | -5,84 | |
0,6300 | -6,63 | |
20,480 | -7,33 | |
2,5000 | -18,83 | |
2,2752 | -32,80 |
Beitrag zu dieser Diskussion schreiben
Hier noch mal was zu den Q. Zahlen :
Shares in 3D Systems were down more than 12% in pre-market trading Thursday after the firm reported earnings and revenue that fell short of expectations.
Q2 EPS came in at $0.16 a share versus forecasts for $0.18. Revenue hit $151.5 million against $162.3 million expected.
Inventory climbed to $90 million versus $86 million forecast, and gross margin came in at 47.8% versus 51% forecast.
CEO Avi Reichental said spending on new product launches held profits back this quarter but that underlying trends remained sound.
"While transitional forces temporarily pressured our gross profit margin, a detailed examination of the specific drivers, confirms that the fundamentals of our business are intact and our gross profit margins are poised to rebound and resume their expansion trajectory," he said.
It's been a shaky year for 3D Systems and its chief competitor, Stratasys. We've previously discussed why we think the 3-D printing industry faces a hype problem. Here's a chart showing the two firms' returns YTD:
Shares in 3D Systems were down more than 12% in pre-market trading Thursday after the firm reported earnings and revenue that fell short of expectations.
Q2 EPS came in at $0.16 a share versus forecasts for $0.18. Revenue hit $151.5 million against $162.3 million expected.
Inventory climbed to $90 million versus $86 million forecast, and gross margin came in at 47.8% versus 51% forecast.
CEO Avi Reichental said spending on new product launches held profits back this quarter but that underlying trends remained sound.
"While transitional forces temporarily pressured our gross profit margin, a detailed examination of the specific drivers, confirms that the fundamentals of our business are intact and our gross profit margins are poised to rebound and resume their expansion trajectory," he said.
It's been a shaky year for 3D Systems and its chief competitor, Stratasys. We've previously discussed why we think the 3-D printing industry faces a hype problem. Here's a chart showing the two firms' returns YTD:
Antwort auf Beitrag Nr.: 47.408.090 von bluechip56 am 31.07.14 15:21:06hm, wenn man sich den Chart anschaut, nachdem Q1 am 29.04 berichtet wurde, ging es vom Tagestief 31,70 EUR innerhalb eines Monats auf 41,70 EUR.
Die Shortquote ist schon seit Monaten sehr hoch, das hat auch zu dem kurzen Anstieg auf die 50 EUR geführt, als Übernahmegerüchte aufkamen.
Bin damals bei 37 EUR rein...
Die Shortquote ist schon seit Monaten sehr hoch, das hat auch zu dem kurzen Anstieg auf die 50 EUR geführt, als Übernahmegerüchte aufkamen.
Bin damals bei 37 EUR rein...
Hab nochmal rescherchiert. Es sind extrem viele Shortpositionen getätigt worden.
Bin bei 33€ eingestiegen, also noch im Plus. Überlege die 3€ mitzunehmen und evtl. bei noch tieferem Kurs neu einzusteigen.
Bin bei 33€ eingestiegen, also noch im Plus. Überlege die 3€ mitzunehmen und evtl. bei noch tieferem Kurs neu einzusteigen.
Sieht leider gar nicht gut aus. Umsatz nur $151.51 Mio. geschaetzt wurden $162.28 million.
Q2 Earnings call läuft grad. Die Zahlen sehen wohl nicht so gut aus... "3D Systems Trampled Beneath Horrendous Earnings/Sales Defects"
http://tickrwatch.com/news/2014/07/id14870-3d-systems-trampl…
http://tickrwatch.com/news/2014/07/id14870-3d-systems-trampl…
Heute über 12% Kursrückgang- Warum?
sieht nicht so aus!
Wollen wir mal hoffen, dass dies morgen positiv aufgenommen wird.
3D Systems Announces Purchase of Simbionix for $120M in Cash
http://www.benzinga.com/news/14/07/4743459/update-3d-systems…
3D Systems (NYSE: DDD) announced today that it entered into a definitive agreement to acquire Simbionix for $120 million in cash, subject to customary closing adjustments. Simbionix is the global leader in 3D virtual reality surgical simulation and training with 60+ interventional procedures across 8 specialties through 16 simulation platforms — a complementary building block that expands 3DS's breadth and reach within the open-ended 3D healthcare field. The transaction is expected to be completed within the next 30 days, subject to customary closing conditions. Upon closing, 3DS expects this acquisition to be immediately accretive to its cash generation and to its non-GAAP earnings per share.
"Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical," said Avi Reichental, President and Chief Executive Officer, 3DS.
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are revolutionizing the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.
"3D Systems is the recognized 3D healthcare leader and they have an exceptional track record of commercially deploying innovative virtual surgery and medical device products and services," said Gary Zamler, Simbionix Corporation CEO. "We couldn't be more excited to join this fine organization and look forward to accelerate our growth by enhancing the entire 3D digital thread for the benefit of our customers worldwide."
The recent acquisition of industry leader Medical Modeling brought to 3DS world-class clinical capabilities in Virtual Surgical Planning (VSP®), guiding and instrumenting of complex personalized surgical procedures, production at scale of 3D printed implants, and delivery of a wide variety of 3D printed patient-specific medical devices.
In addition to synergistic technology and products, Simbionix brings to 3DS global sales channels and deep clinical relationships to accelerate the adoption of best medical practices, to advance clinical performance, and to optimize procedural outcomes. The company's products can be found in simulation centers, hospitals, colleges and other educational facilities in over 60 countries.
The company plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS and immediately pursue synergistic integration opportunities leveraging the combined resources and expertise to advance 3DS' healthcare portfolio further and faster.
Management plans to include a more detailed discussion of this transaction as part of its previously scheduled conference call and simultaneous webcast to review its financial results for the second quarter and first six months of 2014 at 9:00am ET on July 31, 2014. The company also plans to file its second quarter earnings release at 8:30 a.m. ET and its Form 10-Q before the NYSE market opens.
Date: Thursday, July 31, 2014
Time: 9:00 a.m. Eastern Time
Read more: http://www.benzinga.com/news/14/07/4743459/update-3d-systems…#ixzz3906xrb2S
http://www.benzinga.com/news/14/07/4743459/update-3d-systems…
3D Systems (NYSE: DDD) announced today that it entered into a definitive agreement to acquire Simbionix for $120 million in cash, subject to customary closing adjustments. Simbionix is the global leader in 3D virtual reality surgical simulation and training with 60+ interventional procedures across 8 specialties through 16 simulation platforms — a complementary building block that expands 3DS's breadth and reach within the open-ended 3D healthcare field. The transaction is expected to be completed within the next 30 days, subject to customary closing conditions. Upon closing, 3DS expects this acquisition to be immediately accretive to its cash generation and to its non-GAAP earnings per share.
"Simbionix is a perfect match for our healthcare business and its powerful technology, products, channels and domain expertise expands our 3D healthcare capabilities from the training room to the operating room, and extends our first mover advantage in this fast growing vertical," said Avi Reichental, President and Chief Executive Officer, 3DS.
Headquartered in Cleveland, Ohio with a research and development center in Israel, Simbionix pioneered patient-specific simulation with FDA-cleared solutions that are changing the way preparation for individual surgeries are carried out. Its proprietary simulation and training products are revolutionizing the way physicians practice and master surgical procedures with improved learning that can favorably impact patient outcomes.
"3D Systems is the recognized 3D healthcare leader and they have an exceptional track record of commercially deploying innovative virtual surgery and medical device products and services," said Gary Zamler, Simbionix Corporation CEO. "We couldn't be more excited to join this fine organization and look forward to accelerate our growth by enhancing the entire 3D digital thread for the benefit of our customers worldwide."
The recent acquisition of industry leader Medical Modeling brought to 3DS world-class clinical capabilities in Virtual Surgical Planning (VSP®), guiding and instrumenting of complex personalized surgical procedures, production at scale of 3D printed implants, and delivery of a wide variety of 3D printed patient-specific medical devices.
In addition to synergistic technology and products, Simbionix brings to 3DS global sales channels and deep clinical relationships to accelerate the adoption of best medical practices, to advance clinical performance, and to optimize procedural outcomes. The company's products can be found in simulation centers, hospitals, colleges and other educational facilities in over 60 countries.
The company plans to operate Simbionix under the continued leadership of Gary Zamler, CEO of Simbionix, who will become Vice President and General Manager, Simbionix Products for 3DS and immediately pursue synergistic integration opportunities leveraging the combined resources and expertise to advance 3DS' healthcare portfolio further and faster.
Management plans to include a more detailed discussion of this transaction as part of its previously scheduled conference call and simultaneous webcast to review its financial results for the second quarter and first six months of 2014 at 9:00am ET on July 31, 2014. The company also plans to file its second quarter earnings release at 8:30 a.m. ET and its Form 10-Q before the NYSE market opens.
Date: Thursday, July 31, 2014
Time: 9:00 a.m. Eastern Time
Read more: http://www.benzinga.com/news/14/07/4743459/update-3d-systems…#ixzz3906xrb2S
22.03.24 · globenewswire · 3D Systems |
12.03.24 · globenewswire · 3D Systems |
05.03.24 · globenewswire · 3D Systems |
28.02.24 · globenewswire · 3D Systems |
21.02.24 · globenewswire · 3D Systems |
14.02.24 · globenewswire · 3D Systems |
08.02.24 · globenewswire · 3D Systems |
29.01.24 · globenewswire · 3D Systems |
10.01.24 · globenewswire · 3D Systems |
08.01.24 · globenewswire · 3D Systems |